A New Combination Treatment for Big Pharma GlaxoSmithKline?

Pharmaceutical company GlaxoSmithKline (NYSE: GSK  ) recently gained approval for two cancer drugs --- Mekinist and Tafinlar --- but the Food and Drug Administration recently announced that a combination treatment consisting of these two drugs has been given priority review status. In the following video from The Motley Fool's show Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the details behind this news and the potential impact on GlaxoSmithKline's business.

Cash in on big pharma 
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The relevant video segment can be found between 3:25-6:01.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2643747, ~/Articles/ArticleHandler.aspx, 10/1/2014 8:37:55 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement